Montelukast

立即咨询

Montelukast

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

158966-92-8

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议

产品介绍

化学性质

Storage	Store at -20°C
M.Wt	586.18
Cas No.	158966-92-8
Formula	C₃₅H₃₆ClNO₃S
Solubility	≥100mg/mL in DMSO; ≥10mg/mL in Ethanol; Insoluble in H2O
Chemical Name	(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid
Canonical SMILES	CC(C)(O)C1=CC=CC=C1CC[C@@H](SCC2(CC2)CC(O)=O)C3=CC=CC(/C=C/C4=CC=C5C(C=C(Cl)C=C5)=N4)=C3
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Montelukast is a potent, selective and orally-active antagonist of the cysteinyl leukotriene 1 (CysLT1) receptor, with an IC50 value of 4.9 nM in HEK293 cell membranes expressing human CysLT1 receptors. The CysLT1 receptor is a receptor for cysteinyl leukotrienes (e.g. LTC₄, LTD₄, and LTE₄) which mediate allergic and hypersensitivity reactions in a variety of inflammatory disorders, in particular asthma. Montelukast has been introduced clinically for the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction.

References:

1. Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Molecular Pharmacology, 1999, 56(3): 657-663.

2. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opinion on Pharmacotherapy, 2007, 8(13): 2173-2187.

3.Eum SY, Maghni K, Hamid Q, et al. Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. American Journal of Respiratory Cell and Molecular Biology, 2003, 28(1): 25-32.

试验操作

Animal experiment:[3]
Animal models	A mouse model of allergic asthma
Dosage form	3 and 10 mg/kg Administered by gavage
Applications	Montelukast inhibited ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in bronchoalveolar lavage fluid in a mouse model of allergic asthma when administered at doses of 3 and 10 mg/kg.
Note	The technical data provided above is for reference only.
	References: 1. Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Molecular Pharmacology, 1999, 56(3): 657-663. 2. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opinion on Pharmacotherapy, 2007, 8(13): 2173-2187. 3.Eum SY, Maghni K, Hamid Q, et al. Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. American Journal of Respiratory Cell and Molecular Biology, 2003, 28(1): 25-32.